P
Palatin Technologies, Inc. (PTN)
ASE – Real Time Price. Currency in USD
19.99
-0.66 (-3.20%)
At close: Mar 27, 2026, 4:00 PM EDT
21.10
+1.11 (5.55%)
After-hours: Mar 27, 2026, 6:22 PM EDT
Get all premium features to the best stock analysis tool
ASE – Real Time Price. Currency in USD
19.99
-0.66 (-3.20%)
At close: Mar 27, 2026, 4:00 PM EDT
21.10
+1.11 (5.55%)
After-hours: Mar 27, 2026, 6:22 PM EDT
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
| Name | Position |
|---|---|
| Burns McClellan | Vice President of Investor Relations |
| Dr. Carl Spana Ph.D. | Co-Founder, President, CEO & Director |
| Dr. Michael B. Raizman M.D. | Chief Medical Officer |
| Mr. James E. Hattersley B.A., M.S. | Senior Vice President of Business Development |
| Mr. John Dodd Ph.D. | Senior Vice President of Preclinical Development |
| Mr. Robert Jordan | Senior Vice President of Program Operations |
| Mr. Stephen A. Slusher Esq. | Chief Legal Officer |
| Date | Type | Document |
|---|---|---|
| 2025-12-19 | 8-K/A | form8-ka.htm |
| 2025-11-14 | 10-Q | ptn_10q.htm |
| 2025-05-05 | S-1/A | ptn_s1a.htm |
| 2025-04-10 | 8-K | ptn_8k.htm |
| 2025-04-02 | RW | ptn_rw.htm |
| 2025-03-31 | S-1 | ptn_s1.htm |
| 2025-03-07 | DRS | filename1.htm |
| 2025-02-13 | 10-Q | ptn_10q.htm |
| 2025-02-10 | 8-K | ptn_8k.htm |
| 2024-12-16 | 8-K | ptn_8k.htm |
| Mr. Stephen T. Wills CPA, MST |
| CFO, COO, Executive VP, Treasurer & Secretary |